These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9783262)

  • 1. Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis.
    Sharma SK; Singh BR
    J Nat Toxins; 1998 Oct; 7(3):239-53. PubMed ID: 9783262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemagglutinin-33 of type A botulinum neurotoxin complex binds with synaptotagmin II.
    Zhou Y; Foss S; Lindo P; Sarkar H; Singh BR
    FEBS J; 2005 Jun; 272(11):2717-26. PubMed ID: 15943806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological properties of Hn-33 purified from type A Clostridium botulinum.
    Sharma SK; Singh BR
    J Nat Toxins; 2000 Nov; 9(4):357-62. PubMed ID: 11126514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protease-resistant novel hemagglutinin purified from type A Clostridium botulinum.
    Fu FN; Sharma SK; Singh BR
    J Protein Chem; 1998 Jan; 17(1):53-60. PubMed ID: 9491928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins.
    Kukreja R; Chang TW; Cai S; Lindo P; Riding S; Zhou Y; Ravichandran E; Singh BR
    Toxicon; 2009 May; 53(6):616-24. PubMed ID: 19673075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular properties of a hemagglutinin purified from type A Clostridium botulinum.
    Sharma SK; Fu FN; Singh BR
    J Protein Chem; 1999 Jan; 18(1):29-38. PubMed ID: 10071926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-apoptotic activity of hemagglutinin-33 and botulinum neurotoxin and its implications to therapeutic and countermeasure issues.
    Kumar R; Zhou Y; Ghosal K; Cai S; Singh BR
    Biochem Biophys Res Commun; 2012 Jan; 417(2):726-31. PubMed ID: 22182409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cloning, expression, purification, and characterization of biologically active recombinant hemagglutinin-33, type A botulinum neurotoxin associated protein.
    Zhou Y; Paturi S; Lindo P; Shoesmith SM; Singh BR
    Protein J; 2007 Jan; 26(1):29-37. PubMed ID: 17211684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of purification on the bioavailability of botulinum neurotoxin type A.
    Cheng LW; Onisko B; Johnson EA; Reader JR; Griffey SM; Larson AE; Tepp WH; Stanker LH; Brandon DL; Carter JM
    Toxicology; 2008 Jul; 249(2-3):123-9. PubMed ID: 18538461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain.
    Li L; Singh BR
    Protein Expr Purif; 1999 Dec; 17(3):339-44. PubMed ID: 10600450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preparation of neurotoxin and hemagglutinin from Clostridium botulinum A and characterization of its neurotoxin].
    Vinogradova ID; Uvarova RN; Ivanov KK; Kazdobina IS; Bulatova TI
    Biokhimiia; 1983 May; 48(5):788-96. PubMed ID: 6409167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridium botulinum serotype D neurotoxin and toxin complex bind to bovine aortic endothelial cells via sialic acid.
    Yoneyama T; Miyata K; Chikai T; Mikami A; Suzuki T; Hasegawa K; Ikeda T; Watanabe T; Ohyama T; Niwa K
    FEMS Immunol Med Microbiol; 2008 Dec; 54(3):290-8. PubMed ID: 18801042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular structure and immunochemical properties of highly purified hemagglutinin from Clostridium botulinum type A].
    Ivanova LG; Blagoveshchenskiĭ VA; Vinogradova ID; Kolesnikova VA; Ugriumova GA
    Biokhimiia; 1983 Sep; 48(9):1548-54. PubMed ID: 6414537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Electrophoretic analysis on the proteolytic decomposition of of FSH preparations].
    Khalaf H; Neumann U; Rimpler M
    Dtsch Tierarztl Wochenschr; 1995 Oct; 102(10):396-9. PubMed ID: 8591740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins.
    Bryant AM; Cai S; Singh BR
    Toxicon; 2013 Sep; 72():126-32. PubMed ID: 23811077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity.
    Lee JC; Yokoyama T; Hwang HJ; Arimitsu H; Yamamoto Y; Kawasaki M; Takigawa T; Takeshi K; Nishikawa A; Kumon H; Oguma K
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):201-11. PubMed ID: 17692094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains.
    Rao S; Starr RL; Morris MG; Lin WJ
    Foodborne Pathog Dis; 2007; 4(2):201-7. PubMed ID: 17600487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A.
    Sharma S; Zhou Y; Singh BR
    Protein Expr Purif; 2006 Feb; 45(2):288-95. PubMed ID: 16143544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate recognition strategy for botulinum neurotoxin serotype A.
    Breidenbach MA; Brunger AT
    Nature; 2004 Dec; 432(7019):925-9. PubMed ID: 15592454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and stability of the nontoxic component of the botulinum toxin complex.
    Miyata K; Yoneyama T; Suzuki T; Kouguchi H; Inui K; Niwa K; Watanabe T; Ohyama T
    Biochem Biophys Res Commun; 2009 Jun; 384(1):126-30. PubMed ID: 19394306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.